Paul Bonanos
@biobonanos.bsky.social
📤 499
📥 92
📝 452
I write some, I edit some
Biogen is in-licensing Vanqua's C5aR1 program for $70m up front, plus $990m in potential milestones. It's an oral small molecule that complements a mAb in BIIB's pipeline, obtained via its HI-Bio acquisition. Two shots at a pipeline-in-a-product to treat inflammatory diseases.
loading . . .
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE,...
https://www.globenewswire.com/news-release/2025/10/24/3172742/0/en/Biogen-Licenses-Oral-C5aR1-Antagonist-from-Vanqua-Bio-to-Expand-Immunology-Portfolio.html
about 2 hours ago
0
0
0
Ventyx Biosciences' shares are set to double (+100% premarket) following a readout for its CNS-penetrant NLRP3 inhibitor in patients with obesity and CV risk factors:
www.globenewswire.com/news-release...
My colleague
@stephenhansen.bsky.social
wrote about the mechanism last year. Story below.
loading . . .
Treating obesity by quelling inflammation in the brain
Preclinical data suggest NLRP3 could be an important new target for treating obesity. Among the benefits could be oral dosing with fewer side effects than ...
https://www.biocentury.com/article/651740
1 day ago
0
0
0
A deal with Takeda could prove transformative for China-based Innovent Biologics as the partners seek to co-commercialize a bispecific oncology therapy in the U.S. Two other therapies are part of the deal as well; a $1.2 billion upfront component could turn into $11.4 billion in total payments.
loading . . .
With Takeda deal, Innovent takes giant step toward global innovation
Innovent has long sought to evolve from an oncology leader in China to a global innovator. A deal with Takeda on Wednesday around three products represents...
https://www.biocentury.com/article/657355/with-takeda-deal-innovent-takes-giant-step-toward-global-innovation
2 days ago
0
1
0
FGF21 agonist M&A: May 2025: GSK pays $1.2b upfront for Boston Pharma's efimosferin; deal includes $800m in milestones Sept. 2025: Roche buys 89bio for $2.4b upfront, gaining pegozafermin; $1b CVR Today: Novo buys Akero for $4.7b upfront, adding efruxifermin; ~$500m CVR
loading . . .
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet...
https://www.globenewswire.com/news-release/2025/10/09/3163964/0/en/Akero-Therapeutics-to-be-Acquired-by-Novo-Nordisk-for-up-to-5-2-Billion.html
15 days ago
0
1
0
Months after RFK Jr and Marty Makary pushed Peter Marks out of FDA, the former CBER director has taken an SVP role at Lilly.
@steveusdin.bsky.social
has the scoop in
@biocentury.bsky.social
.
loading . . .
Former CBER Director Marks joins Lilly
Peter Marks has joined Eli Lilly and Co. (NYSE:LLY) as SVP for molecule discovery and head of infectious diseases, marking his return to industry after ne...
https://www.biocentury.com/article/657214/former-cber-director-marks-joins-lilly
17 days ago
1
3
5
TCG X's Chen Yu has reasons to be optimistic during a difficult cycle for biotech investors. I spoke with him about the firm's newly disclosed $1.3 billion third fund, its largest yet. Story:
www.biocentury.com/article/6571...
loading . . .
Seeing opportunities among headwinds, TCG X closes $1.3B third fund
Despite headwinds facing the biotech industry, TCG Crossover’s Chen Yu believes the firm will deploy its new $1.3 billion fund during “a...
https://www.biocentury.com/article/657171/seeing-opportunities-among-headwinds-tcg-x-closes-1-3b-third-fund
18 days ago
0
1
0
Lazard's annual biopharma survey is out this morning. I spoke with the firm's David Gluckman about the risks and challenges the industry faces -- and some reasons to be optimistic. Story (no paywall):
www.biocentury.com/article/6570...
loading . . .
Lazard survey: Large caps could consolidate as biopharmas face variety of pressures
Executives and investors surveyed by Lazard increasingly believe consolidation among large-cap biopharmas is likely, while industry leaders see U.S. admini...
https://www.biocentury.com/article/657030/lazard-survey-large-caps-could-consolidate-as-biopharmas-face-variety-of-pressures
about 1 month ago
0
0
0
Our story in
@biocentury.bsky.social
, by
@steveusdin.bsky.social
.
add a skeleton here at some point
about 2 months ago
0
1
0
I spoke with
@jmaraganore.bsky.social
and Clive Meanwell about their new company, Corsera Health. They're seeking to apply the disease interception model to CV health -- identifying risk at an early age and stopping disease from developing in at-risk people. My story:
loading . . .
Corsera: Maraganore, Meanwell bring the disease interception model to CV risk
Rooted in the belief that some cases of cardiovascular disease can be forestalled by identifying risk at an early age, a start-up led by biotech veterans J...
https://www.biocentury.com/article/656856/corsera-maraganore-meanwell-bring-the-disease-interception-model-to-cv-risk
about 2 months ago
0
0
0
What to make of FDA's about-face on Stealth BioTherapeutics' therapy for Barth syndrome? Denied CRL appeal, then signaled it would conduct an unusually quick review -- with a decision due just five weeks after resubmission. Pressure from patient advocates seems to be a factor. Story:
loading . . .
FDA’s about-face on Stealth a positive sign for rare disease therapies?
Following FDA’s denial of a request to reconsider a complete response letter, the agency is now promising an unusually quick review for St...
https://www.biocentury.com/article/656827/fda-s-about-face-on-stealth-a-positive-sign-for-rare-disease-therapies
2 months ago
1
0
1
FDA granted full approval to a treatment for a rare disease based on a single-arm study of 35 evaluable patients, even though its sponsor was seeking accelerated approval. No confirmatory trial needed. And this, from CBER director Vinay Prasad, seems like a signal:
www.fda.gov/news-events/...
2 months ago
0
3
0
VC-backed Expedition Therapeutics, set up to in-license assets from China and develop them in the West, has struck a deal with Fosun for a clinical DPP-1 inhibitor to treat inflammatory and respiratory indications. $17m up front, $628m in milestones. Read about it in BioCentury's Deals Report 👇
loading . . .
Expedition picks Fosun therapy for first China in-licensing agreement: Deals Report
A start-up hunting for in-licensing opportunities in China has closed its first deal, gaining most global rights to a program from Fosun.Backed by Venrock,...
https://www.biocentury.com/article/656716/expedition-picks-fosun-therapy-for-first-china-in-licensing-agreement-deals-report
2 months ago
0
2
0
ICYMI (overnight in many geographies) -- Sanofi is paying $1.15b up front to acquire venture-backed vaccine company Vicebio. Early clinical data were the deal's trigger, chairman Giovanni Mariggi of founding investor Medicxi tells me. Story:
www.biocentury.com/article/6565...
loading . . .
First clinical evidence spurs Sanofi’s takeout of Vicebio for $1.15B up front
Early data emerging from a clinical study of the first product derived from Vicebio’s vaccine platform have spurred Sanofi’s decision to acqu...
https://www.biocentury.com/article/656546/first-clinical-evidence-spurs-sanofi-s-takeout-of-vicebio-for-1-15b-up-front
3 months ago
1
3
0
Good morning
#biosky
! Merck/MSD is paying $10b to acquire Verona Pharma, obtaining an approved PDE3/PDE4 dual inhibitor for COPD. $107/share price is a 23% premium over Tuesday's close.
www.merck.com/news/merck-t...
loading . . .
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade -...
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Merck to hold investor call at 8 a.m. ET today ...
https://www.merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec/
4 months ago
1
3
0
reposted by
Paul Bonanos
Joshua J. Friedman
4 months ago
READ THE COMPLAINT:
storage.courtlistener.com/recap/gov.us...
add a skeleton here at some point
30
4534
1362
SpliceBio's new round is the largest ever -- by a lot -- for a Spain-based biotech, according to BioCentury's BCIQ database. We've been watching the life sciences ecosystem grow in Spain for some time, and early SpliceBio investor Ysios has been a major driver:
www.biocentury.com/article/6410...
add a skeleton here at some point
4 months ago
1
3
0
Intellia NTLA is -28% just after the morning bell. The biotech disclosed a case of liver toxicity in its Phase 3 amyloidosis study, here in an 8-K and apparently on a private call with analysts last evening:
www.sec.gov/ix?doc=/Arch...
5 months ago
0
1
0
Here's a $60m series A for Vima, a newly launched company "with a singular focus: to change the lives of patients with dystonia." That's from co-founder/chairman David Grayzel of Atlas Venture, which led the round. Release here, management team in screenshot:
www.globenewswire.com/news-release...
5 months ago
0
1
0
We had noted the slowdown in follow-on activity amid high volatility this year, with no substantial NASDAQ offerings at all by biotechs during April. The overnight offering from Taysha ($200m last evening), looks like the biggest by a biotech since March. Story:
www.biocentury.com/article/6558...
loading . . .
No follow-ons in April as drought crosses five-week threshold: Finance Report
For the first time in at least six years, public life sciences companies disclosed zero follow-on fundings of $25 million or more in a calendar month,...
https://www.biocentury.com/article/655831/no-follow-ons-in-april-as-drought-crosses-five-week-threshold-finance-report
5 months ago
1
1
0
RBL, the venture studio formed last year with ties to Rice University and KdT Ventures, has just introduced its first biotech spinout. Sentinel BioTherapeutics will present Phase I data at ASCO for its IL-2 program for immuno-oncology. Our October story on RBL:
www.biocentury.com/article/6539...
loading . . .
Why Rice is launching a venture studio in Houston’s emerging biotech ecosystem
The founders of Rice University’s new venture studio believe they can incubate and launch multiple new biotechs each year, capitalizing on a maturi...
https://www.biocentury.com/article/653954/why-rice-is-launching-a-venture-studio-in-houston-s-emerging-biotech-ecosystem
5 months ago
1
3
0
A patient has passed away in Rocket Pharma’s Phase II study of its gene therapy for Danon disease. The study is under clinical hold and Rocket is evaluating next steps.
ir.rocketpharma.com/news-release...
5 months ago
0
2
0
Good morning
#biosky
! Today Biogen is paying City Therapeutics $46m up front, including a $30m equity investment, to develop RNAi medicines, starting with a CNS target. $1b biobucks + royalties. Release:
www.globenewswire.com/news-release...
loading . . .
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise...
https://www.globenewswire.com/news-release/2025/05/27/3088497/0/en/Biogen-and-City-Therapeutics-Announce-Strategic-Research-Collaboration-to-Develop-Select-Novel-RNAi-based-Therapies.html
5 months ago
0
2
0
reposted by
Paul Bonanos
Gregory Koblentz
5 months ago
That giant sucking sound you hear is 80 years of US investment in soft power going down the drain China to donate $500 million to WHO, stepping into gap left by U.S.
www.washingtonpost.com/world/2025/0...
loading . . .
China to donate $500 million to WHO, stepping into gap left by U.S.
Beijing will replace the United States as the organization’s top state donor, expanding its influence as the U.S. retreats from international cooperation.
https://www.washingtonpost.com/world/2025/05/21/china-who-donation-500-million/
1
45
13
BioMarin is buying Inozyme for $4/share, or $270m; it's a 182% premium over Thursday's close of $1.42. Data are due in early 2026 from a Phase III study of $INZY's enzyme replacement therapy for ENPP1 deficiency. Release:
loading . . .
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected...
https://investors.biomarin.com/news/news-details/2025/BioMarin-Strengthens-Enzyme-Therapy-Business-with-Acquisition-of-Inozyme-Pharma/default.aspx
5 months ago
0
1
0
GSK is buying Boston Pharma’s lead asset, an FGF21 agonist for liver disease, for $1.2B up front + $800m milestones. The former Novartis molecule drives a strong return for Boston backer Gurnet Point. Release:
www.gsk.com/en-gb/media/...
A little background:
www.biocentury.com/article/6462...
loading . . .
Kornowski shifts gears at Boston Pharma, sets NASH program as top priority
Seven years after Gurnet Point launched Boston Pharma, new CEO Sophie Kornowski is leading a transition away from the company’s prior model of bring...
https://www.biocentury.com/article/646295/kornowski-shifts-gears-at-boston-pharma-sets-nash-program-as-top-priority
5 months ago
1
2
0
add a skeleton here at some point
5 months ago
0
0
0
reposted by
Paul Bonanos
Scott Gottlieb, MD
6 months ago
My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"
loading . . .
How to stop the shift of drug discovery from the U.S. to China
U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.
https://www.statnews.com/2025/05/06/how-to-stop-the-shift-of-drug-discovery-from-the-u-s-to-china/
2
50
19
The latest biotech to accept a buyout from Tang Capital-backed Concentra: It's Kronos Bio, the company that was until recently led by Norbert Bischofberger. CDK9 discontinued in November; laid off most staff. $112m cash at Dec. 31; complex CVR.
loading . . .
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (
https://www.globenewswire.com/news-release/2025/05/01/3072392/0/en/Kronos-Bio-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-0-57-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html
6 months ago
0
0
0
Novartis promised more "value-creating bolt-ons" during yesterday's conference call. Today, the pharma is buying Regulus Therapeutics for $7/share ("$0.8 billion"), with a CVR that could double the price to $1.7b. Regulus' anti-miR oligo for ADPKD is in Phase 1b.
loading . . .
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
https://www.prnewswire.com/news-releases/regulus-therapeutics-enters-into-agreement-to-be-acquired-by-novartis-ag-302442023.html
6 months ago
0
1
0
reposted by
Paul Bonanos
6 months ago
FDA misses PDUFA goal for Stealth’s Barth syndrome treatment It isn’t clear whether staffing cuts or loss of FDA champions have caused FDA to miss the PDUFA goal for an ultrarare disease therapy.
www.biocentury.com/article/655776
loading . . .
FDA misses PDUFA goal for Stealth’s Barth syndrome treatment
FDA has missed another PDUFA review deadline, this time for a treatment that a small biotech is developing for an ultrarare disease. Stealth Biotherapeutic...
https://www.biocentury.com/article/655776
0
2
2
A few words on this morning's Merck KGaA/SpringWorks deal: Two rare tumor treatments, a takeout consummated after months of rumors, and relief from an M&A drought:
www.biocentury.com/article/6557...
loading . . .
Eight-year-run for Pfizer spinout Springworks culminates in Merck KGaA buyout
The takeout of Springworks by Merck KGaA will fortify the German company’s oncology business with a pair of approved drugs for rare tumors, while al...
https://www.biocentury.com/article/655759/eight-year-run-for-pfizer-spinout-springworks-culminates-in-merck-kgaa-buyout
6 months ago
0
1
2
reposted by
Paul Bonanos
Scott Gottlieb, MD
6 months ago
Steve Usdin writing in BioCentury: “It’s official: FDA says its cuts are delaying drug regulation — Layoffs, lack of access to journals slow response FDA says”
7
82
62
Two key management moves at Galapagos: - CEO Paul Stoffels (ex-JNJ CSO) is retiring this year, but will remain chairman - Ex-Neumora CEO Henry Gosebruch will be CEO of the planned GLPG spinout Release:
www.globenewswire.com/news-release...
Background ($):
www.biocentury.com/article/6546...
loading . . .
Makeover for Gilead-Galapagos deal to yield newco primed for BD
What has become of Galapagos a little more than five years after its major partnership with Gilead is far from what the partners had envisioned for the meg...
https://www.biocentury.com/article/654640/makeover-for-gilead-galapagos-deal-to-yield-newco-primed-for-bd
6 months ago
0
3
3
If LLY's +11% premarket stock move holds, it'd gain about $75 billion in market cap. New oral GLP-1 data in diabetic patients is the driver:
www.prnewswire.com/news-release...
6 months ago
1
0
0
I hadn't heard of Earendil Labs -- this may be its first announcement, datelined Middletown, Delaware -- but it's receiving $125m up front from Sanofi for rights to two bispecifics (α4β7xTL1A, TL1AxIL23) for IBD/autoimmune disease. $1.72b biobucks, plus royalties.
www.prnewswire.com/news-release...
loading . . .
Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases
/PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that...
https://www.prnewswire.com/news-releases/earendil-labs-announces-worldwide-exclusive-license-agreement-with-sanofi-for-next-generation-bispecific-antibodies-for-autoimmune-and-inflammatory-bowel-diseases-302431020.html
6 months ago
0
2
0
reposted by
Paul Bonanos
7 months ago
RFK Jr cited pseudo-science to justify holding up of Novavax COVID vaccine. He said single-antigen vaccines don’t protect against respiratory diseases. There are 2 FDA-approved sgl antigen vaccines for RSV. And data on Novavax solid, FDA reviewers said.
www.biocentury.com/article/655591
2
6
4
More competition in the IgA nephropathy arena as Novartis wins accelerated approval of Vanrafia atrasentan. No REMS, apparently satisfying a $2/share CVR tied to Novartis' 2023 acquisition of Chinook.
www.prnewswire.com/news-release...
7 months ago
0
0
0
I'm hearing from
@steveusdin.bsky.social
that another key official has been forced out from FDA. Peter Stein, longtime director of CDER’s Office of New Drugs, faced demotion and resigned. BioCentury story coming today.
7 months ago
1
3
0
Novo is paying Lexicon $75m up front for rights to an oral therapy targeting ACSL5 to treat obesity; the non-incretin treatment is still preclinical.
www.globenewswire.com/news-release...
loading . . .
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and...
https://www.globenewswire.com/news-release/2025/03/28/3051285/0/en/Lexicon-Pharmaceuticals-Announces-Exclusive-License-Agreement-with-Novo-Nordisk-for-LX9851.html
7 months ago
1
2
0
Good morning
#biosky
! Merck is paying $200m for ex-Greater China rights to an Lp(a) program from Jiangsu Hengrui, now in Phase 2 testing in China. Deal includes $1.77m in biobucks. Recall: AZ paid CSPC $100m in October for rights to an Lp(a) disruptor.
www.businesswire.com/news/home/20...
.
7 months ago
0
2
0
A few words on Amvuttra's label expansion this evening to include the larger ATTR indication with cardiomyopathy -- helping Alnylam fulfill its ambition to reach profitability this year:
www.biocentury.com/article/6554...
loading . . .
Amvuttra’s label expansion lifts Alnylam toward five-year goals
FDA’s expansion Thursday of Amvuttra’s label to include amyloidosis patients with cardiomyopathy should position Alnylam to satisfy most of t...
https://www.biocentury.com/article/655419/amvuttra-s-label-expansion-lifts-alnylam-toward-five-year-goals
7 months ago
0
1
0
I had a word with Sofinnova's Graziano Seghezzi about how the firm will deploy €165m to back companies in what is now the largest biotech accelerator in Europe:
www.biocentury.com/article/6553...
loading . . .
Strategics back Sofinnova Partners’ ‘pan-European’ accelerator in €165M fund
European venture firm Sofinnova Partners has closed a new fund dedicated to supporting companies moving through its Biovelocita accelerator, a strategy it ...
https://www.biocentury.com/article/655367/strategics-back-sofinnova-partners-pan-european-accelerator-in-165m-fund
7 months ago
1
3
2
Curevo will put a new $110m round toward development of its Shringrix competitor, which it believes has tolerability advantages over the incumbent shingles vaccine. I spoke with the company, new board member Moncef Slaoui (ex-GSK) and lead investor Medicxi. Story:
www.biocentury.com/article/6553...
loading . . .
With Medicxi’s backing, Curevo takes aim at Shingrix with $110M series B
With a new $110 million series B led by Medicxi, Seattle-based Curevo is moving a potential competitor to blockbuster shingles vaccine Shingrix toward...
https://www.biocentury.com/article/655350/with-medicxi-s-backing-curevo-takes-aim-at-shingrix-with-110m-series-b
7 months ago
0
5
1
reposted by
Paul Bonanos
Stephen Hansen
8 months ago
add a skeleton here at some point
0
2
1
Shares of Arvinas $ARVN have dipped as much as 50% in the early going today, following its announcement that targeted ER degrader vepdegestrant led to a PFS benefit only in ESR1-mutant ER+/HER2- breast cancer patients, and not in a Phase III study's ITT population. M/cap now ~$620m.
loading . . .
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial | Arvinas
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – V...
https://ir.arvinas.com/news-releases/news-release-details/arvinas-and-pfizer-announce-positive-topline-results-phase-3
8 months ago
0
1
0
J&J won't exercise its option on Genmab's CD38-targeting Hexabody, despite some clinical evidence of efficacy in a head-to-head study vs. Darzalex Faspro; Genmab won't invest further in the program either.
www.globenewswire.com/news-release...
loading . . .
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and...
https://www.globenewswire.com/news-release/2025/03/10/3039878/0/en/Genmab-Announces-Johnson-Johnson-Decision-Regarding-HexaBody-CD38.html
8 months ago
0
0
0
reposted by
Paul Bonanos
Stephen Hansen
8 months ago
#GLP1
sales continue to boom thanks to
#obesity
market expansion
#biosky
#medsky
www.biocentury.com/article/655202
1
4
2
reposted by
Paul Bonanos
Jordi Xiol
8 months ago
CytomX/Amgen discontinue masked EGFR T Cell Engager It seems intuitively hard to get to therapeutic exposures if both sides of the bispecific antibody are masked. More encouraging data with Janux' PSMA bispecific where only CD3 arm is masked $CTMX $AMGN $JANX $VIR
ir.cytomx.com/news-release...
loading . . .
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update | CytomX Therapeutics, Inc.
- Continued progress with lead program, CX-2051 (EpCAM PROBODY ® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY ® Interferon-alpha 2b) Phase 1a translational data in advanced melanoma expected in 2H
https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-2024-financial-results-and
0
1
1
reposted by
Paul Bonanos
Batman or halo
8 months ago
Trump claimed the Biden administration spent $8 million "making mice transgender." The White House tried to back up this number with records of funding for research into cancer, asthma, and HIV, some of which used *transgenic* (genetically modified) mice.
loading . . .
Trump Decried Millions Spent 'Making Mice Transgender.' It Was Cancer and Asthma Research
President Trump falsely claimed that Biden spent $8 million on 'making mice transgender,' but the real research was for human health.
https://www.rollingstone.com/politics/politics-news/trump-transgender-mice-medical-research-1235289439/
776
11096
4539
Jazz Pharma is adding an oncology product via the takeout of Chimerix for ~$935m, 72% premium. Dordaviprone, under review for a type of brain cancer, has a PDUFA date of Aug. 18; it’s PRV-eligible too.
www.globenewswire.com/news-release...
loading . . .
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial...
https://www.globenewswire.com/news-release/2025/03/05/3037278/25619/en/Jazz-Pharmaceuticals-to-Acquire-Chimerix-Further-Diversifying-Oncology-Portfolio.html
8 months ago
0
2
1
Load more
feeds!
log in